Company: ZVRA
Filing Date: 2025-04-29
Form Type: DEFC14A
Source: 0000897069-25-000885
Chunk: 17

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-29
Form: DEFC14A
Chunk 17
---
 providing strategic guidance on FDA interactions, regulatory filings, drug development, and business transactions for pharmaceutical and biotechnology companies. Since 2022, he has consulted for organizations including Zevra, Corium, and Sydnexis, advising on regulatory approvals, investment strategies, and corporate structuring. Previously, Dr. Mickle served as President and Chief Executive Officer of Zevra from 2010 until 2023, where he led the company’s transition from a development-stage to a commercial-stage entity, securing multiple business partnerships and raising over $500 million in equity and debt financing. Dr. Mickle resigned as Chief Executive Officer of the Company effective January 6, 2023, and as President of the Company effective April 25, 2023. He also served as a director of the Company from its inception until the Company’s 2023 annual meeting of the stockholders. After his resignation as President of Zevra in April 2023, Dr. Mickle served as a consultant for Zevra with respect to the development and approval of arimoclomol and other matters as requested until October 31, 2024. The Company paid Dr. Mickle approximately $320,000 in 2023 and approximately $400,000 in 2024 for his consulting services. For information on compensation paid to Dr. Mickle as an officer of the Company, please see the section of the Company’s proxy statement labelled “Executive Compensation – Details of Our Compensation Program – Pay Versus Performance Table,” which is incorporated herein by reference. Mr. Travis C. Mickle, PhD, has over 25 years of pharmaceutical industry experience, including founding the Company, serving as President and Chief Executive Officer of Zevra from 2010 to 2023, and leading the development of multiple approved products. Earlier in his career, he was Lead Scientist at New River Pharmaceuticals, where he discovered and developed VYVANSE®, a multi-billion-dollar ADHD treatment. Dr. Mickle holds a PhD in Bio-Organic Chemistry from the University of Iowa and is named 12 as an inventor on over 250 U.S. patents. His expertise spans drug discovery, regulatory strategy, corporate finance, and pharmaceutical commercialization. Dr. Mickle does not currently hold any position or office with the Company or any corporation or organization that is a parent, subsidiary, or affiliate of the Company. In concluding that Dr. Mickle should serve as a director of the Company, the Proponent considered his extensive experience within